306 related articles for article (PubMed ID: 28535578)
1. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso NN; Hassan R
Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad S; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad SM; Wang A; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD008605. PubMed ID: 33851429
[TBL] [Abstract][Full Text] [Related]
4. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Brown J; Amso NN
Cochrane Database Syst Rev; 2011 Jun; (6):CD002811. PubMed ID: 21678336
[TBL] [Abstract][Full Text] [Related]
5. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Brown J; Amso NN
Cochrane Database Syst Rev; 2011 Feb; (2):CD002811. PubMed ID: 21328256
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
Farquhar C; Rombauts L; Kremer JA; Lethaby A; Ayeleke RO
Cochrane Database Syst Rev; 2017 May; 5(5):CD006109. PubMed ID: 28540977
[TBL] [Abstract][Full Text] [Related]
7. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
Weiss NS; Kostova E; Nahuis M; Mol BWJ; van der Veen F; van Wely M
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010290. PubMed ID: 30648738
[TBL] [Abstract][Full Text] [Related]
8. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2002; (3):CD002811. PubMed ID: 12137659
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
10. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline for preventing ovarian hyperstimulation syndrome.
Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
[TBL] [Abstract][Full Text] [Related]
12. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
[TBL] [Abstract][Full Text] [Related]
13. Luteal phase support for assisted reproduction cycles.
van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009154. PubMed ID: 26148507
[TBL] [Abstract][Full Text] [Related]
14. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Tso LO; Costello MF; Albuquerque LET; Andriolo RB; Macedo CR
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD006105. PubMed ID: 33347618
[TBL] [Abstract][Full Text] [Related]
15. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
[TBL] [Abstract][Full Text] [Related]
16. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
Youssef MA; Mourad S
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
[TBL] [Abstract][Full Text] [Related]
17. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
Youssef MA; Abou-Setta AM; Lam WS
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
[TBL] [Abstract][Full Text] [Related]
18. Fresh versus frozen embryo transfers in assisted reproduction.
Zaat T; Zagers M; Mol F; Goddijn M; van Wely M; Mastenbroek S
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD011184. PubMed ID: 33539543
[TBL] [Abstract][Full Text] [Related]
19. Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation.
Reavey J; Vincent K; Child T; Granne IE
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008720. PubMed ID: 27852101
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Franik S; Eltrop SM; Kremer JA; Kiesel L; Farquhar C
Cochrane Database Syst Rev; 2018 May; 5(5):CD010287. PubMed ID: 29797697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
